Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and ipilimumab in dMMR/MSI metastatic colorectal cancer resistant to anti-PD-1 (NIPIRESCUE)
2024-516313-20-00Phase 2Authorised
- Sponsor
- GERCOR
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in colorectal cancer (CRC), sponsored by GERCOR. Planned start Oct 2024; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-516313-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516313-20-00.